1
|
Li Q, Geng T, Li H, Zheng S, Svedlund S, Gan L, Egnell AC, Gao S, Chen R, Hu P. Analysis of the pharmacokinetics and efficacy of RBD1016 - A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model. Heliyon 2024; 10:e31924. [PMID: 38841435 PMCID: PMC11152740 DOI: 10.1016/j.heliyon.2024.e31924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 05/23/2024] [Accepted: 05/23/2024] [Indexed: 06/07/2024] Open
Abstract
Small interference RNA (siRNA) is a class of short double-stranded RNA molecules that cause mRNA degradation through an RNA interference mechanism and is a promising therapeutic modality. RBD1016 is a siRNA drug in clinical development for the treatment of chronic Hepatitis B Virus (HBV) infection, which contains a conjugated with N-acetylglucosamine moiety that can facilitate its hepatic delivery. We aimed to construct a semi-mechanistic model of RBD1016 in pre-clinical animals, to elucidate the pharmacokinetic/pharmacodynamic (PK/PD) profiles in mice and PK profiles in monkeys, which can lay the foundation for potential future translation of RBD1016 PK and PD from the pre-clinical stage to the clinic stage. The proposed semi-mechanistic PK/PD model fitted PK and PD data in HBV transgenic mice well and described plasma and liver concentrations in the monkeys well. The simulation results showed that our model has a reasonable predictive ability for Hepatitis B surface antigen (HBsAg) levels after multiple dosing in mice. Further PK and PD data for RBD1016, including clinical data, will assist in refining the model presented here. Our current effort focused on model building for RBD1016, we anticipate that the model could apply to other GalNAc-siRNA drugs.
Collapse
Affiliation(s)
- Qian Li
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Taohua Geng
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China
| | - Haiyan Li
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China
| | - Shuquan Zheng
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China
| | - Sara Svedlund
- Ribocure Pharmaceuticals AB, Medicinaregatan 8A, Gothenburg, Sweden
| | - Liming Gan
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China
- Ribocure Pharmaceuticals AB, Medicinaregatan 8A, Gothenburg, Sweden
| | - Ann-Charlotte Egnell
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China
- Ribocure Pharmaceuticals AB, Medicinaregatan 8A, Gothenburg, Sweden
| | - Shan Gao
- Suzhou Ribo Life Science Co. Ltd., Jiangsu, 215300, China
| | - Rui Chen
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Pei Hu
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
2
|
Wong YL, Ramanathan A, Yuen KM, Mustafa WMW, Abraham MT, Tay KK, Rahman ZAA, Chen Y. Comparative sera proteomics analysis of differentially expressed proteins in oral squamous cell carcinoma. PeerJ 2021; 9:e11548. [PMID: 34178453 PMCID: PMC8199918 DOI: 10.7717/peerj.11548] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Accepted: 05/11/2021] [Indexed: 11/20/2022] Open
Abstract
Background Oral squamous cell carcinoma (OSCC) has increased in incidence from 1990 to 2017, especially in South and Southeast Asia. It is often diagnosed at an advanced stage with a poor prognosis. Therefore, early detection of OSCC is essential to improve the prognosis of OSCC. This study aims to identify the differentially expressed serum proteins as potential biomarkers for oral squamous cell carcinoma (OSCC). Methods Comparative proteomics profiling of serum samples from OSCC patients, oral potentially malignant disorder (OPMD) patients, and healthy individuals were performed using two-dimensional gel electrophoresis (2-DE) coupled with mass spectrometry (MS) (n = 60) and bioinformatics analysis. The enzyme-linked immunosorbent assay (ELISA) (n = 120) and immunohistochemistry (IHC) (n = 70) were used to confirm our findings. Results The 2-DE analysis revealed that 20 differentially expressed proteins were detected in OPMD and OSCC (p < 0.05). Bioinformatics analysis indicated that the activation of classical complement, liver X receptor/retinoid X receptor (LXR/RXR) activation, and acute phase response signaling pathway are associated with the development and progression of OSCC. Most of the detected proteins are acute-phase proteins and were related to inflammation and immune responses, including apolipoprotein A-I (APOA1), complement C3 (C3), clusterin (CLU), and haptoglobin (HP). The expression levels of CLU and HP in ELISA are consistent with the findings from the 2-DE analysis, except for the mean serum level of HP in OPMD, whereby it was slightly higher than that in control. IHC results demonstrated that CLU and HP are significantly decreased in OSCC tissues. Conclusion Decreased expression of CLU and HP could serve as complementary biomarkers of OSCC. These proteins may assist in predicting the outcomes of OSCC patients. However, a larger cohort is needed for further investigation.
Collapse
Affiliation(s)
- Yin-Ling Wong
- Department of Oral & Craniofacial Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Anand Ramanathan
- Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.,Oral Cancer Research & Coordinating Centre, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Kar Mun Yuen
- Oral Health Program, Ministry of Health, Federal Government Administrative Centre, Putrajaya, Malaysia
| | | | - Mannil Thomas Abraham
- Oral Health Program, Ministry of Health, Federal Government Administrative Centre, Putrajaya, Malaysia
| | - Keng Kiong Tay
- Oral Health Program, Ministry of Health, Federal Government Administrative Centre, Putrajaya, Malaysia
| | - Zainal Ariff Abdul Rahman
- Department of Oral & Maxillofacial Clinical Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.,Oral Cancer Research & Coordinating Centre, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Yeng Chen
- Department of Oral & Craniofacial Sciences, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia.,Oral Cancer Research & Coordinating Centre, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| |
Collapse
|
3
|
Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. J Clin Med 2020; 9:jcm9020323. [PMID: 31979338 PMCID: PMC7074125 DOI: 10.3390/jcm9020323] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 01/13/2020] [Accepted: 01/21/2020] [Indexed: 02/07/2023] Open
Abstract
Alpha fetoprotein (AFP) has been used as a serologic indicator of hepatocellular carcinoma (HCC). We aimed to identify an HCC-specific serum biomarker for diagnosis using a multiplexed proteomic technique in HCC patients with normal AFP levels. A total of 152 patients were included from Guro Hospital, Korea University. Among 267 identified proteins, 28 and 86 proteins showed at least a two-fold elevation or reduction in expression, respectively. Multiple reaction monitoring (MRM) analysis of 41 proteins revealed 10 proteins were differentially expressed in patients with liver cirrhosis and HCC patients with normal AFP. A combination of tripartite motif22 (Trim22), seprase, and bone morphogenetic protein1 had an area under receiver operating characteristic of 0.957 for HCC diagnosis. Real-time PCR and western blot analysis of the paired tumor/non-tumor liver tissue in HCC revealed a reduced expression of Trim22 in the tumor tissue. Also, serum levels of Trim22 were significantly reduced in HCC patients with normal AFP compared to those with liver cirrhosis (p = 0.032). Inhibition of Trim22 increased cellular proliferation in human hepatoma cell lines, whereas overexpression of Trim22 decreased cellular proliferation in hepatoma cell lines. In conclusion, the combination of three serum markers improved the chance of diagnosing HCC. MRM-based quantification of the serum protein in patients with normal AFP provides the potential for early diagnosis of HCC.
Collapse
|
4
|
Hashemi SMA, Sarvari J, Fattahi MR, Dowran R, Ramezani A, Hosseini SY. Comparison of ISG15, IL28B and USP18 mRNA levels in peripheral blood mononuclear cells of chronic hepatitis B virus infected patients and healthy individuals. GASTROENTEROLOGY AND HEPATOLOGY FROM BED TO BENCH 2019; 12:38-45. [PMID: 30949318 PMCID: PMC6441482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
AIM The purpose of this study was to evaluate the expression level of Interferon-stimulated Gene 15 (ISG15), Interleukin28B (IL28B) or IFN-lambda-3 and Ubiquitin specific peptidase 18 (USP18) genes in Peripheral Blood Mononuclear Cells (PBMCs) of patients with chronic active and inactive hepatitis B in comparison with healthy individuals. BACKGROUND Despite the presence of the vaccine for hepatitis B virus (HBV), it remains a public health challenge. The effort to uncover the immune genes attributed to infection outcome is going through. METHODS This Cross-sectional study was conducted on hepatitis B infected patients that were admitted to the Clinic of Liver diseases, Shiraz, January-November 2016. Patients were divided into two groups including active and inactive chronic regarding relevant World Gastroenterology Organization Global Guideline. They were mono-infected with HBV, and HCV or HIV co-infection was excluded from the study. Gene expression analysis was performed on fresh PBMCs samples with the help of Real-time PCR method. RESULTS Interleukin 28B gene expression showed no statistically significant difference between the three studied groups (P>0.05). The expression level of ISG15 was significantly higher in the healthy control group compared to active (P= 0.0068) and inactive chronic subjects (P<0.0001). Similarly, USP18 expression level in the control group was also significantly higher compared to the active (P= 0.0228) and inactive chronic patients (P=0. 0226). CONCLUSION The results of this study showed that the expression level of ISG15 and USP18 but not IL28B were higher in healthy individuals than in those infected with HBV. This difference expression may highlight the role of ISG15 and USP18 in the immune-related mechanism of HBV infection.
Collapse
Affiliation(s)
| | - Jamal Sarvari
- Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran,Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mohammad Reza Fattahi
- Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Razieh Dowran
- Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Amin Ramezani
- Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Seyed Younes Hosseini
- Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
5
|
Dalal K, Khorate P, Dalal B, Chavan R, Bhatia S, Kale A, Shukla A, Shankarkumar A. Differentially expressed serum host proteins in hepatitis B and C viral infections. Virusdisease 2018; 29:468-477. [PMID: 30539049 PMCID: PMC6261891 DOI: 10.1007/s13337-018-0484-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2018] [Accepted: 08/17/2018] [Indexed: 12/18/2022] Open
Abstract
Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection often lead to hepatocellular carcinoma (HCC), which is mostly detected in advanced stage. Hence, its early detection is of paramount importance using a biomarker having sensitivity and specificity both. The present study highlights differentially expressed host proteins in response to HBV/HCV infection at different stages. Comparative proteomic study was done by two-dimensional gel electrophoresis followed by mass spectrometry. Sera from each of chronically infected, liver cirrhosis and HCC in HBV or HCV infection along with controls were selected. Analysis of functional association between differentially expressed proteins with viral hepatitis was extensively carried out. Forty-three differentially expressed spots (≥ 1.5 fold; P < 0.05) on two-dimensional gel electrophoresis were corresponded to 28 proteins by mass spectrometry in variable liver diseases. Haptoglobin protein levels were decreased upon disease progression to HCC due to HBV infection. The other proteins expressed differentially are ceruloplasmin, serum paraoxonase 1, retinol binding protein and leucine rich alpha 2 proteins in plasma maybe associated to HBV HCC. Whereas, upregulation of C4a/C4b showed it as a reliable marker in patients with end stage liver disease related to HCV infection. ApolipoproteinA1 levels in liver diseases in both HBV and HCV infection corresponding to healthy controls may be a common marker for early diagnosis and disease monitoring. Protein interaction studies by extensive pathway analysis using bioinformatics tools such as EnrichNet application and STRING revealed significant associations with specific infections.
Collapse
Affiliation(s)
- Kruti Dalal
- Transfusion Transmitted Diseases Department, National Institute of Immunohaematology, 13th floor, New Multi-storeyed Bldg, KEM Hospital Campus, Parel, Mumbai, 400 012 India
| | - Priyanka Khorate
- Transfusion Transmitted Diseases Department, National Institute of Immunohaematology, 13th floor, New Multi-storeyed Bldg, KEM Hospital Campus, Parel, Mumbai, 400 012 India
| | - Bhavik Dalal
- Transfusion Transmitted Diseases Department, National Institute of Immunohaematology, 13th floor, New Multi-storeyed Bldg, KEM Hospital Campus, Parel, Mumbai, 400 012 India
| | - Rahul Chavan
- School of Chemical Sciences, UM-DAE Centre for Excellence in Basic Sciences, Mumbai University Campus, Vidyanagari, Kalina, Santacruz (East), Mumbai, 400098 India
| | - Shobna Bhatia
- Department of Gastroenterology, Seth G S Medical College and K E M Hospital, Acharya Donde Marg, Parel, Mumbai, 400 012 India
| | - Avinash Kale
- School of Chemical Sciences, UM-DAE Centre for Excellence in Basic Sciences, Mumbai University Campus, Vidyanagari, Kalina, Santacruz (East), Mumbai, 400098 India
| | - Akash Shukla
- Department of Gastroenterology, Seth G S Medical College and K E M Hospital, Acharya Donde Marg, Parel, Mumbai, 400 012 India
- Present Address: Department of Gastroenterology, Lokmanya Tilak Municipal General Hospital, Sion, Mumbai, 400 022 India
| | - Aruna Shankarkumar
- Transfusion Transmitted Diseases Department, National Institute of Immunohaematology, 13th floor, New Multi-storeyed Bldg, KEM Hospital Campus, Parel, Mumbai, 400 012 India
| |
Collapse
|
6
|
Yamamoto M, Takahashi T, Serada S, Sugase T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Naka T, Mori M, Doki Y. Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. Cancer Sci 2017; 108:2052-2060. [PMID: 28746773 PMCID: PMC5623762 DOI: 10.1111/cas.13329] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 07/14/2017] [Accepted: 07/23/2017] [Indexed: 12/11/2022] Open
Abstract
Gastric cancer is one of the most common malignant tumors. Although improvement in chemotherapy has been achieved, the clinical prognosis of advanced gastric cancer remains poor. Therefore, it is increasingly important to predict the prognosis and determine whether patients should or should not receive neoadjuvant or adjuvant chemotherapy. Leucine‐rich α2‐glycoprotein‐1 (LRG1) is overexpressed during inflammation and is associated with various malignancies. In this study, we assessed LRG1 expression in cancer specimens and in the sera of patients with cancer to clarify the usefulness of LRG1 as a biomarker in gastric cancer. This study enrolled 239 (for immunohistochemical staining; IHC) and 184 (for ELISA) patients with gastric cancer. Results of IHC showed that LRG1 expression was significantly associated with histological type, lymphatic and venous invasion, tumor and node factors, and disease stage. Overall survival was significantly worse in the high LRG1 expression group than in the low LRG1 group (P = 0.0003). Cox multivariate analysis of overall survival revealed that LRG1 expression was an independent prognostic factor (P = 0.0258). Serum LRG1 was significantly higher in gastric cancer patients than in healthy volunteers, and increased as the pathological stage progressed. Furthermore, a significant correlation was revealed between serum LRG1 level and LRG1 expression with IHC (P < 0.0001). Inhibition of LRG1 significantly decreased cell proliferation in vitro (migratory and invasive capacity of gastric cancer cells). These results suggest that LRG1 expression in tumors and serum may be a useful prognostic marker in gastric cancer patients.
Collapse
Affiliation(s)
- Masaaki Yamamoto
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Tsuyoshi Takahashi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.,Laboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Satoshi Serada
- Laboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Takahito Sugase
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.,Laboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Koji Tanaka
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yasuhiro Miyazaki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Tomoki Makino
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yukinori Kurokawa
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Makoto Yamasaki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kiyokazu Nakajima
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Shuji Takiguchi
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Testsuji Naka
- Laboratory of Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan
| | - Masaki Mori
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yuichiro Doki
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
7
|
Yu SJ, Kim H, Min H, Sohn A, Cho YY, Yoo JJ, Lee DH, Cho EJ, Lee JH, Gim J, Park T, Kim YJ, Kim CY, Yoon JH, Kim Y. Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. J Proteome Res 2017; 16:1239-1248. [DOI: 10.1021/acs.jproteome.6b00833] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Su Jong Yu
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Hyunsoo Kim
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Hophil Min
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Areum Sohn
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Young Youn Cho
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Jeong-Ju Yoo
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Dong Hyeon Lee
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Eun Ju Cho
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Jeong-Hoon Lee
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Jungsoo Gim
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Taesung Park
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Yoon Jun Kim
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Chung Yong Kim
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Jung-Hwan Yoon
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| | - Youngsoo Kim
- Department
of Internal Medicine and Liver Research Institute, ‡Department of Biomedical
Engineering, and §Institute of Medical and Biological Engineering, Medical Research
Center, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Korea
- Interdisciplinary
Program in Bioinformatics and ⊥Department of Statistics, Seoul National University, Daehak-dong, Seoul 151-742, Korea
| |
Collapse
|
8
|
Khaghanzadeh N, Nakamura K, Kuramitsu Y, Ghaderi A, Mojtahedi Z. Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach. Oncol Lett 2016; 12:5295-5302. [PMID: 28105238 DOI: 10.3892/ol.2016.5352] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2016] [Accepted: 09/02/2016] [Indexed: 12/30/2022] Open
Abstract
Umbelliprenin (Umb), a natural coumarin, has demonstrated anti-tumor activities, both in vitro and particularly in vivo, in several types of cancer, including lung cancer. The present study aimed to identify molecular targets of Umb using a high-throughput approach. Lung cancer cell lines, QU-DB (large-cell lung carcinoma) and A549 (adenocarcinoma), were treated with Umb. Differentially-expressed proteins were identified using two-dimensional electrophoresis coupled to mass spectrometry. In the QU-DB cells, differential expression of proteins, including downregulation of the tumorigenic protein heat shock protein 90 kDa and upregulation of the potential anti-tumor proteins Nipsnap1 and glycine-tRNA ligase (GRS), suggested that Umb is a strong anti-tumor compound. In the A549 cells, differential expression of proteins indicated possible contradictory effects of Umbregarding tumorigenesis, which included downregulation of the tumorigenic protein cyclophilin and the tumor suppressor MST, and upregulation of stathmin (tumorigenic) and calreticulin. Calreticulun, in addition to GRS in QU-DB cells, stimulates anti-tumor immune responses in vivo. To the best of our knowledge, the present study is the first to use a high-throughput approach to identify targets of Umb in cancer. These molecular targets suggested that Umb may exhibit stronger in vitro anti-tumor activity against the large-cell carcinoma model than the adenocarcinoma model. Furthermore, it has been reported that Umb exhibits higher cytotoxicity against QU-DB cells than A549 cells in vitro, and significant Umb anti-tumor activity against lung cancer in vivo, which is consistent with previously published literature. In each cell type, immune-associated molecules were upregulated, indicating that this naturally occurring compound exhibits marked anti-tumor activity in vivo. However, further studies that investigate the effect of Umb in different in vitro models of cancer are required.
Collapse
Affiliation(s)
- Narges Khaghanzadeh
- Department of Immunology, Hormozgan University of Medical Sciences, Bandar Abbas 79196, Iran; Cancer Biomarkers and Proteomics Lab, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz 71348, Iran
| | - Kazuyuki Nakamura
- Department of Biochemistry and Functional Proteomics, Yamaguchi University, Graduate School of Medicine, Yamaguchi 7538511, Japan
| | - Yasuhiro Kuramitsu
- Department of Biochemistry and Functional Proteomics, Yamaguchi University, Graduate School of Medicine, Yamaguchi 7538511, Japan
| | - Abbas Ghaderi
- Cancer Biomarkers and Proteomics Lab, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz 71348, Iran
| | - Zahra Mojtahedi
- Cancer Biomarkers and Proteomics Lab, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz 71348, Iran
| |
Collapse
|
9
|
Sarvari J, Mojtahedi Z, Kuramitsu Y, Fattahi MR, Ghaderi A, Nakamura K, Erfani N. Comparative Proteomics of Sera From HCC Patients With Different Origins. HEPATITIS MONTHLY 2014; 14:e13103. [PMID: 24497876 PMCID: PMC3909643 DOI: 10.5812/hepatmon.13103] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/23/2013] [Revised: 09/28/2013] [Accepted: 10/29/2013] [Indexed: 12/11/2022]
Abstract
BACKGROUND Hepatocellular carcinoma (HCC), a major fatal cancer worldwide, is induced by different etiological factors in the liver. OBJECTIVES To gain insight into serum protein profiling of HCC with different etiologies. PATIENTS AND METHODS We subjected the sera of HBV-HCC, HCV-HCC, non-B non-C-HCC patients, and healthy volunteers to two-dimensional gel electrophoresis (2-DE) and liquid chromatography tandem mass spectrometry (LC-MS/MS). RESULTS We found 30 differentially expressed protein spots (≥ 1.5 fold P < 0.05) between these two analyses; of them 17 protein spots corresponding to 8 proteins were identified by MS. Transthyretin, leucine rich α-2-glycoprotein, and ficolin 3 were differentially expressed between HBV-related HCC and non-B non-C-HCC sera. Moreover, haptoglobin α-2 isoforms were decreased in HCV-HCC compared to non-B non-CHCC. CONCLUSIONS Serum proteome analyses of HCC with different origins showed a differential protein pattern, presumably related to different hepatopathogenesis in liver induced by different agents. Further studies are required to clarify the importance of identified proteins for early diagnosis of HCC with different origins.
Collapse
Affiliation(s)
- Jamal Sarvari
- Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Zahra Mojtahedi
- Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Yasuhiro Kuramitsu
- Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| | - Mohammad Reza Fattahi
- Department of Internal Medicine, School of Medicine, Shiraz University of Medical sciences, Shiraz, IR Iran
| | - Abbas Ghaderi
- Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Kazuyuki Nakamura
- Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| | - Nasrollah Erfani
- Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
- Corresponding Author: Nasrollah Erfani, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, P.O. Box: 71345-3119, Shiraz, IR Iran. Tel/Fax: +98-7112303687, E-mail:
| |
Collapse
|
10
|
Sarvari J, Mojtahedi Z, Taghavi SAR, Kuramitsu Y, Shamsi Shahrabadi M, Ghaderi A, Nakamura K. Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. HEPATITIS MONTHLY 2013; 13:e8351. [PMID: 24066001 PMCID: PMC3776151 DOI: 10.5812/hepatmon.8351] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2012] [Revised: 12/25/2012] [Accepted: 04/19/2013] [Indexed: 12/11/2022]
Abstract
BACKGROUND Hepatocellular carcinoma is a highly progressive cancer in the case of late diagnosis which is frequently associated with HBV and HCV viral infections. OBJECTIVES To identify differentially expressed serum proteins among three main stages of HCV infection and healthy individuals, and their comparisons with sera from patients with the same stage of HBV infection. PATIENTS AND METHODS Two-dimensional polyacrylamide gel electrophoresis combined with liquid chromatography-tandem mass spectrometry was performed on 47 sera from healthy volunteers, those with chronic active hepatitis, cirrhosis and HCC patients associated with HBV and HCV infections. RESULTS Among these, 62 spots were differentially expressed (≥ 1.5 fold; P < 0.05), of which 42 spots that corresponded to 15 proteins were identified by liquid chromatography-tandem mass spectrometry. CD5-like antigen (CD5L) was differentially expressed between cirrhosis and HCC patients with HCV infection. Leucine-rich α2-glycoprotein (LRG) and haptoglobin (HP) α2 isoforms differed in the HCC that was associated with either HCV or HBV infections. CONCLUSIONS CD5L might be a useful biomarker for early diagnosis of HCC in HCV cirrhotic patients. LRG and HP α2 isoforms could be potential markers for distinguishing viral HCC. Our results also further support the presence of varying molecules involved in hepatocarcinogenesis in HBV when compared with HCV infection.
Collapse
Affiliation(s)
- Jamal Sarvari
- Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, IR Iran
- Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, IR Iran
- Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| | - Zahra Mojtahedi
- Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | | | - Yasuhiro Kuramitsu
- Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| | | | - Abbas Ghaderi
- Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, IR Iran
- Corresponding author: Abbas Ghaderi, Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, IR Iran. Tel: +98-7112303687, Fax: +98-7112304952, E-mail:
| | - Kazuyuki Nakamura
- Department of Biochemistry and Functional Proteomics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
| |
Collapse
|
11
|
Hooshmand S, Ghaderi A, Yusoff K, Karrupiah T, Rosli R, Mojtahedi Z. Downregulation of RhoGDIα increased migration and invasion of ER (+) MCF7 and ER (-) MDA-MB-231 breast cancer cells. Cell Adh Migr 2013; 7:297-303. [PMID: 23563506 DOI: 10.4161/cam.24204] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Rho GDP dissociation inhibitors (RhoGDIs) can inhibit cell motility, invasion, and metastasis in cancer by inactivating the RhoGTPases. A member of RhoGDI family has been consistently shown to interact with estrogen receptor (ER), and change its transcriptional activity. ER is a receptor known to be inversely correlated with cell motility and invasion in breast cancer. The consequence of RhoGDIα activity on migration and invasion of ER (+) and ER (-) breast cancers is not clear. The aim of our study was to investigate the possible opposing effect of RhoGDIα on the migration and invasion of ER (+) MCF7 and ER (-) MDA-MB-231 breast cancer cells. RhoGDIα was downregulated using short interfering RNA (siRNA) and upregulated using GFP-tagged ORF clone of RhoGDIα, and their ability for migration and invasion was assayed using transwell chambers. It was found that the silencing of RhoGDIα in MCF7 and MDA-MB-231 cells significantly increased migration and invasion of these cells into the lower surface of porous membrane of the chambers. Overexpression of RhoGDIα in MCF7 cells suppressed their migration and invasion, but no significant effect was found on MDA-MB-231 cells. Our results indicate that the downregulation of RhoGDIα similarly affects the in vitro migration and invasion of ER (+) MCF7 and ER (-) MDA-MB-231 cells. However, our assays are differently affected by the upregulation of RhoGDIα in these two cell lines and this may be due to the differences in ER expression, primary invasive ability and/or other molecules between these two cell line models which warrant further investigation.
Collapse
Affiliation(s)
- Somayeh Hooshmand
- Cancer Proteomics and Biomarkers Lab, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
| | | | | | | | | | | |
Collapse
|